Monitor upcoming quarterly results for execution against $690M revenue guidance and adoption trends of iDose TR and Epioxa. No immediate trading catalyst from this filing.
Drugs in focus
GKOS drug pipeline →iDose TREX
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2b/3
- Time to market
- Unknown; Phase 2b/3 trials typically take 2-4 years to complete, so potential approval would likely be 2028-2030 at earliest, assuming positive data.
- Next catalyst
- None dated
What to watchMonitor for interim or topline data readouts from the Phase 2b/3 program, which could serve as a catalyst. The next meaningful update may come at a major ophthalmology conference. Meanwhile, iDose TR commercial adoption trends and quarterly earnings are the primary near-term drivers for GKOS stock.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 3 $170.87entry
- T+1 · 4mo ago −0.20%α −2.00% · $170.53
- T+5 · 3mo ago +6.17%α +4.15% · $181.42
- T+20 · 3mo ago +5.09%α +3.85% · $179.56
- T+60 · 21d ago +7.68%α +5.90% · $184.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Glaukos filed an 8-K furnishing an August 2026 investor presentation. The presentation reiterates previously disclosed 2026 revenue guidance of $690M, highlights 85% non-GAAP gross margin, $289M cash with no debt, and a strong pipeline including iDose TR and Epioxa. No new material financial information or guidance changes are introduced.
Key Facts
- 2026 revenue guidance midpoint of $690M, unchanged from 2Q 2026 earnings call on 7/29/2026
- 2Q 2026 non-GAAP gross margin of 85%
- Cash and equivalents of $289M with no debt as of 6/30/2026
- $900M invested in R&D since 2018
- 30% topline growth in 2025 and 20% 10-year revenue CAGR
- iDose TR approved for re-administration (Jan 2026) and Epioxa commercially available (March 2026)
- Multiple late-stage pipeline programs: iDose TRIO (Phase 3b), iDose TREX (Phase 2b/3), Retina XR (Phase 2a)
Financial Impact
No new financial impact; presentation repeats prior guidance and operating metrics
Risk Factors
- Commercial adoption of iDose TR and Epioxa may underperform expectations
- Pipeline clinical trial delays or regulatory setbacks
- Competitive pressure in interventional glaucoma and keratoconus markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001192448-26-000002 |
| Document: gkos-ex99_1.htm | 0001192448-26-000002 |
| Document: 0001192448-26-000002-index-headers.html | 0001192448-26-000002 |
| Document: 0001192448-26-000002-index.html | 0001192448-26-000002 |
| Document: 0001192448-26-000002.txt | 0001192448-26-000002 |
Track record
16 reports on GKOS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $242.67 Now $244.88 +0.91% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $245.72 Now $244.88 −0.34% settles Nov 20
- Nov 6, 202610d ago 8-K Neutral 3/10 Entry $224.41 to $245.72 Now $244.88 +9.12% ▲ +9.50% +6.90% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $224.41 to $245.72 Now $244.88 +9.12% ▲ +9.50% +6.90% vs SPY
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $246.70 to $247.16 Now $244.88 −0.74% ▲ +0.19% +1.10% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $246.70 to $247.16 Now $244.88 −0.74% ▲ +0.19% +1.10% vs SPY
- Oct 30, 202617d ago 144 Neutral 3/10 Entry $237.60 to $224.41 Now $244.88 +3.06% ▼ −5.55% −2.85% vs SPY
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $242.48 to $219.98 Now $244.88 +0.99% ▼ −9.28% −4.55% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $184.53 to $184.89 Now $244.88 +32.70% ▲ +0.20% +1.56% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $186.63 to $189.55 Now $244.88 +31.21% ▲ +1.56% +2.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers